416 related articles for article (PubMed ID: 10831479)
1. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Henderson DC; Cagliero E; Gray C; Nasrallah RA; Hayden DL; Schoenfeld DA; Goff DC
Am J Psychiatry; 2000 Jun; 157(6):975-81. PubMed ID: 10831479
[TBL] [Abstract][Full Text] [Related]
2. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.
Henderson DC; Nguyen DD; Copeland PM; Hayden DL; Borba CP; Louie PM; Freudenreich O; Evins AE; Cather C; Goff DC
J Clin Psychiatry; 2005 Sep; 66(9):1116-21. PubMed ID: 16187768
[TBL] [Abstract][Full Text] [Related]
3. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities.
Henderson DC
J Clin Psychiatry; 2001; 62 Suppl 23():39-44. PubMed ID: 11603884
[TBL] [Abstract][Full Text] [Related]
4. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates.
Lamberti JS; Costea GO; Olson D; Crilly JF; Maharaj K; Tu X; Groman A; Dietz MB; Bushey MP; Olivares T; Wiener K
J Clin Psychiatry; 2005 Jul; 66(7):900-6. PubMed ID: 16013906
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of obesity, lipid and glucose abnormalities in outpatients prescribed clozapine.
Leonard P; Halley A; Browne S
Ir Med J; 2002 Apr; 95(4):119-20. PubMed ID: 12090443
[TBL] [Abstract][Full Text] [Related]
6. Clozapine-associated elevation in serum triglycerides.
Gaulin BD; Markowitz JS; Caley CF; Nesbitt LA; Dufresne RL
Am J Psychiatry; 1999 Aug; 156(8):1270-2. PubMed ID: 10450273
[TBL] [Abstract][Full Text] [Related]
7. A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses.
Kelly AC; Sheitman BB; Hamer RM; Rhyne DC; Reed RM; Graham KA; Rau SW; Gilmore JH; Perkins DO; Peebles SS; VanderZwaag CJ; Jarskog LF
J Clin Psychopharmacol; 2014 Aug; 34(4):441-5. PubMed ID: 24943389
[TBL] [Abstract][Full Text] [Related]
8. The prevalence and clinical-demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine.
Zhang R; Hao W; Pan M; Wang C; Zhang X; Chen DC; Xiu MH; Yang FD; Kosten TR; Zhang XY
Hum Psychopharmacol; 2011 Aug; 26(6):392-6. PubMed ID: 21826737
[TBL] [Abstract][Full Text] [Related]
9. Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-Year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder.
Nemani KL; Greene MC; Ulloa M; Vincenzi B; Copeland PM; Al-Khadari S; Henderson DC
Clin Schizophr Relat Psychoses; 2019; 12(4):168-176. PubMed ID: 29164928
[TBL] [Abstract][Full Text] [Related]
10. [Type 2 diabetes and dyslipidemia. Side effects of "Atypical" neuroleptics?].
Wetterling T
Med Klin (Munich); 2003 Jul; 98(7):364-7. PubMed ID: 12937901
[TBL] [Abstract][Full Text] [Related]
11. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.
Henderson DC; Kunkel L; Nguyen DD; Borba CP; Daley TB; Louie PM; Freudenreich O; Cather C; Evins AE; Goff DC
Acta Psychiatr Scand; 2006 Feb; 113(2):142-7. PubMed ID: 16423166
[TBL] [Abstract][Full Text] [Related]
12. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.
Birkenaes AB; Birkeland KI; Engh JA; Faerden A; Jonsdottir H; Ringen PA; Friis S; Opjordsmoen S; Andreassen OA
J Clin Psychopharmacol; 2008 Apr; 28(2):132-7. PubMed ID: 18344722
[TBL] [Abstract][Full Text] [Related]
13. Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine.
Feng S; Melkersson K
Neuro Endocrinol Lett; 2012; 33(5):493-8. PubMed ID: 23090266
[TBL] [Abstract][Full Text] [Related]
14. Clozapine and associated diabetes mellitus.
Popli AP; Konicki PE; Jurjus GJ; Fuller MA; Jaskiw GE
J Clin Psychiatry; 1997 Mar; 58(3):108-11. PubMed ID: 9108812
[TBL] [Abstract][Full Text] [Related]
15. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study.
Chen CH; Huang MC; Kao CF; Lin SK; Kuo PH; Chiu CC; Lu ML
J Clin Psychiatry; 2013 May; 74(5):e424-30. PubMed ID: 23759461
[TBL] [Abstract][Full Text] [Related]
16. [Schizophrenia and diabetes mellitus: not an improbable combination].
Cohen D; Gispen-de Wied CC
Ned Tijdschr Geneeskd; 2003 May; 147(21):993-6. PubMed ID: 12811967
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.
Henderson DC; Fan X; Copeland PM; Borba CP; Daley TB; Nguyen DD; Zhang H; Hayden D; Freudenreich O; Cather C; Evins AE; Goff DC
Acta Psychiatr Scand; 2007 Feb; 115(2):101-5. PubMed ID: 17244173
[TBL] [Abstract][Full Text] [Related]
18. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment.
Procyshyn RM; Wasan KM; Thornton AE; Barr AM; Chen EY; Pomarol-Clotet E; Stip E; Williams R; Macewan GW; Birmingham CL; Honer WG;
J Psychiatry Neurosci; 2007 Sep; 32(5):331-8. PubMed ID: 17823649
[TBL] [Abstract][Full Text] [Related]
19. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.
Chen CK; Chen YC; Huang YS
Psychiatry Clin Neurosci; 2009 Feb; 63(1):17-22. PubMed ID: 19067997
[TBL] [Abstract][Full Text] [Related]
20. CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine.
Siskind D; Friend N; Russell A; McGrath JJ; Lim C; Patterson S; Flaws D; Stedman T; Moudgil V; Sardinha S; Suetani S; Kisely S; Winckel K; Baker A
BMJ Open; 2018 Mar; 8(3):e021000. PubMed ID: 29500217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
